Novo nordisk share price

The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas.

Research shows urgent need for policies to encourage weight loss and cut disease risk. The EU is missing out on trillions of euros of capital for its businesses. German pharma group finds no unexpected side effects during trial, including at higher doses. Financial Times Close. Search the FT Search. Show more World link World. Show more US link US.

Novo nordisk share price

In order to secure liquidity for both the Novo Nordisk B shares and American Depositary Receipts ADRs and bring price levels in line with market practice for especially the ADRs, the Board of Directors has decided to split the trading units in a two-for-one ratio. After the split, the total number of A shares of nom. DKK 0. Each A-share of nom. DKK 0,10 carries votes. Consequently, the total number of votes relating to the A shares is ,,, votes. After the split, the total number of B shares of nom. Each B-share of nom. DKK 0,10 carries 10 votes. Consequently, the total number of votes relating to the B shares is 34,,, votes. Please find the company announcement regarding the stock split here. Barclays Capital Emily Field, emily.

Cancel Continue.

.

Drugmaker releases promising trial results for a pill and expects to enter China this year. Research shows urgent need for policies to encourage weight loss and cut disease risk. The EU is missing out on trillions of euros of capital for its businesses. Financial Times Close. Search the FT Search. Show more World link World. Show more US link US.

Novo nordisk share price

Investor optimism was driven by Novo Nordisk's reveal on Thursday that a Phase I trial of the pill version of the experimental drug amycretin showed participants lost The Danish drug manufacturer is riding a wave of investor enthusiasm for GLP-1 obesity drugs. JPMorgan's analysts said this week that retail traders had shifted focus to pharma stocks , dumping most Magnificent Seven names in the last week. Read next.

Aot ymir backstory

Stoxx Show more US link US. Oddo Securities Martial Descoutures, martial. European companies. Visual and data journalism. Uh oh Something went wrong while loading Watchlist. All rights reserved. Go to Your Watchlist. Kepler Cheuvreux David Evans, devans keplercheuvreux. Liberum Graham Doyle, graham. Research shows urgent need for policies to encourage weight loss and cut disease risk. Show more Tech link Tech.

Novo Nordisk, of anti-obesity drug Wegovy fame, reveals encouraging initial trial data for new weight loss drug that could potentially overtake Wegovy. Pharmaceutical giant Novo Nordisk has recently overtaken electric vehicle maker Tesla, in terms of market valuation, following upbeat initial trial data for a new obesity drug. Following the launch of Wegovy in June , Novo Nordisk has established itself as a leader in the weight-loss drug sector, making the news of a potential new drug even more highly anticipated.

Consequently, the total number of votes relating to the A shares is ,,, votes. Feb 23 Search Ticker. Why More Are Coming. Jyske Bank Henrik Hallengreen Laustsen, hla jyskebank. All content on FT. Goldman Sachs James Quigley, James. Barclays Capital Emily Field, emily. The EU is missing out on trillions of euros of capital for its businesses. DKK 0,10 carries votes. Symbols Loading No Recent Tickers Visit a quote page and your recently viewed tickers will be displayed here. Last Updated: Mar 1, p. ET by Ciara Linnane. Miracle Or Myth?